Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
129 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Leiomyosarcoma - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Leiomyosarcoma - Pipeline Review, H2 2016', provides an overview of the Leiomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma - The report reviews pipeline therapeutics for Leiomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Leiomyosarcoma therapeutics and enlists all their major and minor projects - The report assesses Leiomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Leiomyosarcoma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Leiomyosarcoma Overview 7 Therapeutics Development 8 Pipeline Products for Leiomyosarcoma - Overview 8 Pipeline Products for Leiomyosarcoma - Comparative Analysis 9 Leiomyosarcoma - Therapeutics under Development by Companies 10 Leiomyosarcoma - Therapeutics under Investigation by Universities/Institutes 11 Leiomyosarcoma - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Leiomyosarcoma - Products under Development by Companies 14 Leiomyosarcoma - Products under Investigation by Universities/Institutes 15 Leiomyosarcoma - Companies Involved in Therapeutics Development 16 Advenchen Laboratories, LLC 16 BeiGene, Ltd. 17 Cell Medica Limited 18 Karyopharm Therapeutics, Inc. 19 Merck & Co., Inc. 20 Millennium Pharmaceuticals Inc 21 Mirati Therapeutics Inc. 22 Novartis AG 23 Pfizer Inc. 24 Vicore Pharma AB 25 Leiomyosarcoma - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 AL-3818 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 axitinib - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 BGB-290 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 C-21 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 CMD-003 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 everolimus - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 mocetinostat - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 pazopanib hydrochloride - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 pembrolizumab - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 sapanisertib - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 selinexor - Drug Profile 109 Product Description 109 Mechanism Of Action 109 R&D Progress 109 Leiomyosarcoma - Dormant Projects 126 Leiomyosarcoma - Discontinued Products 127 Appendix 128 Methodology 128 Coverage 128 Secondary Research 128 Primary Research 128 Expert Panel Validation 128 Contact Us 128 Disclaimer 129
List of Tables
Number of Products under Development for Leiomyosarcoma, H2 2016 8 Number of Products under Development for Leiomyosarcoma - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Leiomyosarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2016 16 Leiomyosarcoma - Pipeline by BeiGene, Ltd., H2 2016 17 Leiomyosarcoma - Pipeline by Cell Medica Limited, H2 2016 18 Leiomyosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 19 Leiomyosarcoma - Pipeline by Merck & Co., Inc., H2 2016 20 Leiomyosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 21 Leiomyosarcoma - Pipeline by Mirati Therapeutics Inc., H2 2016 22 Leiomyosarcoma - Pipeline by Novartis AG, H2 2016 23 Leiomyosarcoma - Pipeline by Pfizer Inc., H2 2016 24 Leiomyosarcoma - Pipeline by Vicore Pharma AB, H2 2016 25 Assessment by Monotherapy Products, H2 2016 26 Number of Products by Stage and Target, H2 2016 28 Number of Products by Stage and Mechanism of Action, H2 2016 30 Number of Products by Stage and Route of Administration, H2 2016 32 Number of Products by Stage and Molecule Type, H2 2016 34 Leiomyosarcoma - Dormant Projects, H2 2016 126 Leiomyosarcoma - Discontinued Products, H2 2016 127
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
